Cerebrolysin

What is Cerebrolysin?

Cerebrolysin is a drug made from pig brain. It is not a single peptide but a standardized mixture of small peptides and free amino acids produced by breaking down purified porcine brain proteins with enzymes.⁴

It is made by the Austrian company EVER Neuro Pharma, formerly Ebewe Pharma.⁴ It has been in medical use for decades. It is widely used for acute ischemic stroke in Russia, Eastern Europe, China and other Asian and post-Soviet countries.³ In many of those markets it is also given for vascular dementia, traumatic brain injury and Alzheimer's disease.

Cerebrolysin is not approved by the FDA. In the US it attracts interest as a nootropic, a supposed cognitive enhancer, and it is imported through informal channels. That use has little relation to the hospital settings where it has been studied.

How Cerebrolysin works

The brain makes its own growth factors, proteins that help nerve cells survive, form connections and recover from injury. Cerebrolysin is thought to imitate some of these signals. The idea is that after a stroke, head injury or long-term damage from poor blood flow, the peptide mixture helps nerve cells survive and rewire. Because it is a complex mixture, no single ingredient has been shown to be responsible.

More precisely, Cerebrolysin is an enzymatic hydrolysate containing low-molecular-weight peptides and free amino acids, proposed to have neurotrophic and neuroprotective activity.² Laboratory studies suggest effects resembling those of the brain's own neurotrophic factors, including support for neuronal survival, synaptic plasticity and neurogenesis, along with anti-inflammatory activity. The pharmacokinetics of a mixture are hard to define, and no half-life has been established for its active components.

What the research shows on Cerebrolysin

Cerebrolysin has more human trial data than almost any other compound in this category, but independent reviews have found that evidence weak and inconsistent.

For acute ischemic stroke, the Cochrane review has been updated several times. The 2020 version included seven randomized trials with 1,601 participants. It found moderate-quality evidence that Cerebrolysin probably has little or no effect on all-cause death and no clear effect on total serious adverse events, but an increase in non-fatal serious adverse events.³ The 2017 version reached the same conclusion: no demonstrated clinical benefit for acute ischemic stroke.⁴ Earlier versions with fewer trials pointed the same way.⁶⁵ The manufacturer supported four of the seven trials in some form.³

The quality problems are specific. In the 2017 stroke review, five of six trials were judged at high risk of bias from incomplete outcome data, and four at high risk from selective reporting.⁴ Those flaws tend to make a treatment look better than it is, so even the neutral results should be read with that in mind.

For vascular dementia, a 2019 Cochrane review identified six trials with 597 participants. Courses of intravenous Cerebrolysin improved cognition and global function, but the evidence was rated very low quality, the trials had high risk of bias, and all trials with funding details were industry-supported. The authors cautioned that any benefit might be too small to matter clinically.²

A 2025 meta-analysis of treatments for vascular cognitive impairment, covering 173 trials, found small to moderate cognitive improvements for Cerebrolysin, similar to cholinesterase inhibitors, memantine and exercise, while noting substantial heterogeneity and few adequately sized trials.⁷

For traumatic brain injury, Cerebrolysin is among several agents still being evaluated. A 2025 review found that no neuroprotective drug has yet proven effective for moderate to severe TBI.¹

Studied for: Vascular dementia, Stroke recovery, Traumatic brain injury, Alzheimer's research.

Cerebrolysin reference data

Cerebrolysin dosage in published research

How Cerebrolysin is used in practice

Where it is approved, Cerebrolysin is usually given as a series of daily intravenous infusions, often in hospital.² Courses commonly last 10 to 20 days and are sometimes repeated. Smaller doses are sometimes given by intramuscular injection.

In the US, it reaches consumers through imports from countries where it is sold, through some integrative and anti-aging clinics, and through online sellers. Nootropic users often inject small volumes under the skin or into muscle, a route and dosing pattern that does not match the trials. Imported and gray-market vials carry risks of counterfeiting, poor storage and broken cold chains. Some proponents also promote it for conditions such as PTSD-related cognitive problems, based on its proposed neurotrophic action rather than trial results.⁸

Because Cerebrolysin is derived from animal tissue, manufacturing controls matter. Products from the licensed manufacturer are made under pharmaceutical standards in the countries where it is approved. Products of unknown origin offer no such assurance.

Cerebrolysin risks and side effects

In trials, overall adverse event rates were similar to placebo, but the stroke reviews found more non-fatal serious adverse events with Cerebrolysin. In one subgroup using 30 mL daily for 10 days, that increase was more pronounced.³ Commonly reported side effects include dizziness, sweating, agitation, headache and injection-site reactions.

Its prescribing information lists epilepsy and severe kidney impairment as reasons not to use it. Caution is advised with certain antidepressants, including MAO inhibitors. Pregnancy data are lacking.

Using it as a nootropic in healthy people has not been studied at all. There is no evidence that it improves memory or focus in people without brain disease, and long-term effects of repeated self-administered courses are unknown. Injecting an animal-derived product without medical oversight also carries a risk of allergic reaction.

Reported side effects

Alternatives to Cerebrolysin

For acute ischemic stroke, the proven treatments are clot-dissolving drugs such as alteplase or tenecteplase given within hours, mechanical thrombectomy for large vessel blockages, and organized stroke rehabilitation. Prevention relies on blood pressure control, antiplatelet or anticoagulant drugs as appropriate, statins and smoking cessation.

For vascular dementia and cognitive impairment, options include cholinesterase inhibitors such as donepezil, memantine, physical exercise and cognitive rehabilitation, which showed comparable small benefits in the 2025 meta-analysis, along with strict vascular risk control.⁷ For early Alzheimer's disease, the anti-amyloid antibodies lecanemab and donanemab are FDA approved for selected patients.

Questions for a clinician

• What evidence applies to my situation, and at what level?
• What established alternatives should I consider first?
• What monitoring would be necessary, and how often?
• Can this be prescribed at all where I live, or only sold for research?